Liver/Biliary Disorders News

Primary care providers and other specialists often refer patients to gastroenterologists with any liver-related health concerns, as they are the first touch point for newly diagnosed patients or those living with chronic liver disease.

In 2020, a model in Hepatology projected an impending “critical shortage” of adult and pediatric hepatology providers in the U.S., posing a potential challenge as an increasing number of individuals are expected to present for care.

Adherence to treatment with glucagon-like peptide-1 receptor agonists may lower the long-term risk for major adverse liver outcomes among patients with chronic liver disease and type 2 diabetes, according to data in Gut.

The FDA has granted 510(k) clearance to Nanox’s HealthFLD artificial intelligence software to aid clinicians in the detection of fatty liver associated with hepatic steatosis, according to a company press release.

The FDA has granted fast track designation to GSK’s bepirovirsen, a triple action investigational antisense oligonucleotide, for the treatment of chronic hepatitis B virus infection, according to a manufacturer release.

Physicians treating older veterans with dementia “should consider underlying cirrhosis” and use Fibrosis-4 as a screening tool to uncover reversible factors, such as hepatic encephalopathy, that may be associated with cognitive decline.

Individuals with alcohol-related liver disease and frequent health care utilization were at greater risk for mortality and hospital readmission, respectively, according to a cohort study of alcohol-related hospitalizations in Canada.

Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.

A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to address the “urgent need” for anti-scarring therapies for individuals with liver disease.

Incidence of new portal vein thrombosis was higher after transarterial chemoembolization for hepatocellular carcinoma compared with microwave or radiofrequency ablation, although researchers reported no clinically significant sequalae.